Department of Urology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Int J Clin Oncol. 2020 May;25(5):892-898. doi: 10.1007/s10147-020-01632-x. Epub 2020 Feb 11.
Identifying the predictive factors for tumor recurrence after partial nephrectomy (PN) is useful to determine patients who require careful observation after surgery. Therefore, we investigated recurrence after partial nephrectomy (PN) in patients with clinical T1 renal cell carcinoma (RCC) and analyzed predictive factors for recurrence-free survival (RFS).
This study included 1227 patients who underwent PN for clinical T1 RCC and retrospectively investigated patients' characteristics and tumor factors that are associated with tumor recurrence.
The median patient age was 59 years, and the median tumor size was 30 mm. Although 970 (74%) and 319 (26%) patients had clinical T1a and T1b RCCs, respectively, 20 patients (1.6%) were upstaged to pathological T3a. A positive surgical margin was found in 19 (1.5%) patients. The distribution of surgical approaches was open surgery in 428 (35%) patients and minimally invasive surgery in 799 (65%) patients. With a median follow-up of 35 months (Interquartile range 19-55 months), 39 (3.2%) patients, including ten with local recurrence, five with recurrence in the ipsilateral kidney, and 28 with other organs or lymph-nude, developed recurrence. The 3-year RFS was 99%, and the median recurrence time from PN was 19 months (interquartile range: 11-37 months). Multivariate analysis identified high grade tumor and upstaging to pT3a as significant predictors for worse RFS.
Patients with high grade tumors and tumors upstaged to pT3 had a high risk of worse RFS, which suggested that careful monitoring is required for such patients after PN, even if a good prognosis is achieved in patients with clinical T1 RCC.
确定肾部分切除术(PN)后肿瘤复发的预测因素有助于确定术后需要密切观察的患者。因此,我们研究了临床 T1 期肾细胞癌(RCC)患者 PN 后的复发情况,并分析了无复发生存(RFS)的预测因素。
本研究纳入了 1227 例接受 PN 治疗的临床 T1 RCC 患者,回顾性分析了与肿瘤复发相关的患者特征和肿瘤因素。
患者的中位年龄为 59 岁,肿瘤的中位大小为 30mm。虽然分别有 970 例(74%)和 319 例(26%)患者的临床 T1a 和 T1b 期 RCC,但 20 例(1.6%)患者被升级为病理 T3a 期。19 例(1.5%)患者的切缘阳性。手术方式的分布为开放手术 428 例(35%),微创手术 799 例(65%)。中位随访时间为 35 个月(四分位距 19-55 个月),39 例(3.2%)患者发生了复发,包括 10 例局部复发,5 例同侧肾复发,28 例其他器官或淋巴结转移。3 年 RFS 为 99%,PN 后复发的中位时间为 19 个月(四分位距:11-37 个月)。多因素分析显示,高级别肿瘤和升级为 pT3a 是 RFS 较差的显著预测因素。
高级别肿瘤和升级为 pT3a 的患者发生 RFS 较差的风险较高,这提示即使在临床 T1 RCC 患者中预后良好,也需要对这些患者进行密切监测。